share_log

HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target

Benzinga ·  May 17, 2023 06:16

HC Wainwright & Co. analyst Andrew Fein reinstates Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment